
a molecular weight of 385.8, its empirical formula is $C_{17}H_{18}FN_3O_3 \cdot HCl \cdot H_2O$ and its chemical structure is as follows:



[0006] Ciprofloxacin was previously classified as a moderate inhibitor of CYP1A2 by the FDA [FDA Draft Guidance for Industry Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling, September 2006]; this description was recently revised in February 2012 [FDA Draft Guidance for Industry Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, February 2012].

SUMMARY

[0006a] In a first aspect of the present disclosure, there is provided a use of pirfenidone for the manufacture of a medicament for treating a patient in need of pirfenidone therapy, wherein the pirfenidone therapy comprises reducing the dosage of pirfenidone to be administered to a patient to about 1602 mg/day during concomitant administration of ciprofloxacin at a dose of 750 mg twice daily (1500 mg/day).

~~[0006b] In a second aspect of the present disclosure, there is provided a package or kit comprising (a) pirfenidone, optionally in a container, and (b) a package insert, package label, instructions or other labeling for the uses of pirfenidone according to the first aspect.~~

~~[0006c] In a third aspect of the present disclosure, there is provided a use of (a) pirfenidone, optionally in a container, and (b) a package insert, package label, instructions or other labeling for the manufacture of a package or kit for the uses of pirfenidone according to the first aspect.~~

[0007] The disclosure generally relates to improved use of pirfenidone and methods of administering pirfenidone to a patient in need of pirfenidone therapy, and to corresponding methods of preparing or packaging pirfenidone medicaments, containers, packages and kits. The disclosure also relates to pirfenidone for corresponding uses in treating a patient in need of pirfenidone therapy, including use of a novel therapeutic dose.

[0008] The present disclosure is based in part on the discovery that concomitant administration of pirfenidone at a dose of 801 mg (e.g., given three times per day for a total daily dose of 2403 mg/day) and ciprofloxacin at a dose of 750 mg (e.g., given twice daily for

CLAIMS

1. Use of pirfenidone for the manufacture of a medicament for treating a patient in need of pirfenidone therapy, wherein the pirfenidone therapy comprises reducing the dosage of pirfenidone to be administered to a patient to about 1602 mg/day during concomitant administration of ciprofloxacin at a dose of 750 mg twice daily (1500 mg/day).

2. The use according to claim 1 wherein the use is for avoiding the potential for a reduced clearance of pirfenidone or the potential for an increased exposure to pirfenidone.

3. The use according to any one of claim 1 or claim 2 wherein the total daily dose of pirfenidone is to be administered to the patient in divided doses three times per day, with food.

4. The use according to any of claims 1-3 wherein the pirfenidone is to be administered in unit dosage forms that are capsules or tablets.

5. The use according to claim 4 wherein the amount of pirfenidone in the unit dosage form is 267 mg.

6. The use according to any one of claims 1-5 wherein the patient has idiopathic pulmonary fibrosis (IPF).

7. The use according to any of claims 1-5 wherein the patient has a fibrotic disorder, inflammatory disorder, or autoimmune disorder.

8. The use according to any of claims 1-5 wherein the patient suffers from a disease selected from idiopathic pulmonary fibrosis, pulmonary fibrosis, bronchiolitis obliterans, chronic lung transplant rejection, scleroderma, primary focal segmental glomerulosclerosis (FSGC) or membranoproliferative glomerulonephritis (MPGN), idiopathic interstitial pneumonia, interstitial lung disease in systemic sclerosis, a fibrosis condition of the lung, ~~autoimmune lung diseases, benign prostate hypertrophy, coronary or myocardial infarction, atrial fibrillation, cerebral infarction,~~ myocardiac fibrosis, musculoskeletal fibrosis, post-surgical adhesions, ~~liver cirrhosis,~~ renal fibrotic disease, fibrotic vascular disease, ~~scleroderma,~~ Hermansky-Pudlak syndrome, neurofibromatosis, ~~Alzheimer's disease, diabetic retinopathy, or skin lesions,~~ lymph node fibrosis associated with

HIV, ~~chronic obstructive pulmonary disease (COPD),~~ inflammatory pulmonary fibrosis, ~~rheumatoid arthritis; rheumatoid spondylitis; osteoarthritis; gout, other arthritic conditions; sepsis; septic shock; endotoxic shock; gram-negative sepsis; toxic shock syndrome; myofacial pain syndrome (MPS); Shigellosis; asthma; adult respiratory distress syndrome; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; glomerular nephritis; scleroderma; chronic thyroiditis; Grave's disease; Ormond's disease; autoimmune gastritis; myasthenia gravis; autoimmune hemolytic anemia; autoimmune neutropenia; thrombocytopenia;~~ pancreatic fibrosis; ~~chronic active hepatitis including~~ hepatic fibrosis; ~~acute or chronic renal disease;~~or renal fibrosis~~; diabetic nephropathy; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke or ischemic injury; neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute or chronic pain; allergies, including allergic rhinitis or allergic conjunctivitis; cardiac hypertrophy, chronic heart failure; acute coronary syndrome; cachexia; malaria; leprosy; leishmaniasis; Lyme disease; Reiter's syndrome; acute synoviitis; muscle degeneration, bursitis; tendonitis; tenosynoviitis; herniated, ruptured, or prolapsed intervertebral disk syndrome; osteopetrosis; thrombosis; silicosis; pulmonary sarcosis; bone resorption diseases, such as osteoporosis or multiple myeloma-related bone disorders; cancer, including but not limited to metastatic breast carcinoma, colorectal carcinoma, malignant melanoma, gastric cancer, or non-small cell lung cancer; graft-versus-host reaction; or auto-immune diseases, such as multiple sclerosis, lupus or fibromyalgia; AIDS or other viral diseases such as Herpes Zoster, Herpes Simplex I or II, influenza virus, Severe Acute Respiratory Syndrome (SARS) or cytomegalovirus; or diabetes mellitus, proliferative disorders (including both benign or malignant hyperplasias), acute myelogenous leukemia, chronic myelogenous leukemia, Kaposi's sarcoma, metastatic melanoma, multiple myeloma, breast cancer, including metastatic breast carcinoma; colorectal. carcinoma; malignant melanoma; gastric cancer; non-small cell lung cancer (NSCLC); bone metastases; pain disorders including neuromuscular pain, headache, cancer pain, dental pain, or arthritis pain; angiogenic disorders including solid tumor angiogenesis, ocular neovascularization, or infantile hemangioma; conditions associated with the cyclooxygenase or lipoxygenase signaling pathways, including conditions associated with prostaglandin endoperoxide synthase-2 (including edema, fever, analgesia, or pain); organ hypoxia; thrombin-induced platelet aggregation; or protozoal diseases~~.

~~9. A package or kit comprising (a) pirfenidone, optionally in a container, and (b) a package insert, package label, instructions or other labeling for the uses of pirfenidone according to any one of claims 1-8.~~

~~10. Use of (a) pirfenidone, optionally in a container, and (b) a package insert, package label, instructions or other labeling for the manufacture of a package or kit for the uses of pirfenidone according to any one of claims 1-8.~~